Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS ...
If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... bispecific antibody in combination with chemotherapy in ...
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...
Earlier this year, Summit Therapeutics and Akeso unveiled new data on their PD-1/VEGF-A bispecific drug, ivonescimab, showing ...
Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...
Rahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath ...
The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...
Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...
The Motley Fool on MSN12d
Is Merck Stock a Buy?Its top-selling treatment, Keytruda, will lose patent protection in a few years ... for a slew of additional indications ...
Mutant RAS, they ... Oct. 31, 2024 — Researchers have shown that the IGFBP3 protein plays a relevant role in human lung development. The results of the study, which used organoids derived from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback